Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Radium-223 chloride (BAY88-8223)
Radium-223 chloride · 3 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Radium-223 dichloride (Xofigo, BAY 88-8223) | EXPERIMENTAL | Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy. |
| Radium-223 chloride (Xofigo, BAY88-8223) | EXPERIMENTAL | The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg). |
| Radium-223 chloride | EXPERIMENTAL | IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks |
| Name | Type | Description |
|---|---|---|
| Radium-223 chloride (BAY88-8223) | DRUG | The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.). |
| Radium-223 chloride (Xofigo®, BAY88-8223) injection | DRUG | Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration |
Inclusion Criteria: * Patient is female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potentia...
Top 20 of 87 competitors
Radium-223 chloride is an investigational small molecule oncology therapy developed by Bayer AG (ticker BAYRY). It has been studied in breast cancer, prostate cancer, and prostatic neoplasms, including patients with bone metastases. It is also known as BAY88-8223 and Alpharadin.
Radium-223 chloride has been studied in prostate cancer, specifically in patients with hormone-refractory prostate cancer that has metastasized to the skeleton. Trials have evaluated its safety, dosimetry, and pharmacokinetics in this population. It is not approved for these uses based on the available data.
Radium-223 chloride is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical trials evaluating the drug in breast cancer and prostate cancer.
Radium-223 chloride is in Phase 2 development. A Phase 2 trial in breast cancer patients with bone-dominant disease has been completed, and two Phase 1 trials in prostate cancer have also been completed. It remains an investigational therapy.
Radium-223 chloride has been studied in three completed trials: NCT01070485, a Phase 2 trial in breast cancer with bone metastases; NCT00748046, a Phase 1 safety and dosimetry trial in hormone-refractory prostate cancer with skeletal metastases; and NCT00667537, a Phase 1 pharmacokinetic trial in prostatic neoplasms.
Yes, Radium-223 chloride is also known as BAY88-8223 and Alpharadin. The name Xofigo is associated with radium-223 chloride as well. These alternative names refer to the same investigational compound developed by Bayer AG.